ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Studies have demonstrated that andrographolide effectively reduces BCR-ABL expression at the protein level, leading to the inhibition of downstream oncogenic signaling pathways and the induction of apoptosis in CML cells, including those resistant to TKIs [114].